Abiomed, Inc. (NASDAQ: ABMD) announced today that Michael R. Minogue,
Chairman, President and Chief Executive Officer, will present at the
2008 Morgan Stanley Global Healthcare...
Abiomed Announces Update on 510(k) Clearance Process for Impella 2.5 Circulatory Support Device
Abiomed, Inc. (NASDAQ: ABMD) today announced an update on the 510(k)
clearance...
CMS Proposes Coverage with Evidence Development (CED) Decision
Abiomed Inc. (NASDAQ: ABMD) recently received a proposed National
Coverage Decision (NCD) from the...
Three of Four FDA Questions on 510(k) Submission Now Resolved, Only
Bench Testing Pending
Abiomed, Inc. (NASDAQ: ABMD) today announced it recently received a...
Abiomed, Inc. (NASDAQ: ABMD), a leading provider of medical devices that provide circulatory support to acute heart failure patients today announced a strategic investment in WorldHeart...
- Provides for Collaboration on Marketing and Clinical Support -
OAKLAND, Calif., Dec. 12 /PRNewswire-FirstCall/ -- (Nasdaq: WHRT, TSX: WHT) -- World Heart Corporation (WorldHeart or the...
Abiomed, Inc. (NASDAQ: ABMD) today announced that Michael R. Minogue, Chairman, President and Chief Executive Officer, will participate on the "Matters of the Heart: Bringing Innovation...
Abiomed, Inc. (NASDAQ: ABMD) announced today that Michael R. Minogue, Chairman, President and Chief Executive Officer, will present at the Piper Jaffray Annual Healthcare Conference on...
Revenue up 5% to $11.4 million
Impella 2.5 High-Risk PCI Pivotal Trial Conditionally Approved in Late Fiscal Q2 2008
Customer Orders of $1.6 million for Impella 2.5 Pivotal Trial...
Abiomed, Inc. (NASDAQ: ABMD) announced today that on Thursday, November 8, 2007, the Company will release second fiscal quarter 2008 results. The Company will host a conference call to...
Abiomed, Inc. (NASDAQ: ABMD), today announced its planned schedule for the global live broadcasts of Impella 2.5 patient procedures at the Cardiovascular Research Foundation’s (CRF)...
Live Broadcasts of Impella Procedures and Leading Clinician Presentations on Recovery
Satellite Symposium: Dr. William O’Neill, Principal Investigator, Impella 2.5 Clinical Trial
...
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD) today announced that the Office of the Drug Controller General (DCGI) in India has granted registration for the...
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed, Inc. (NASDAQ: ABMD) today announced the release of data on its Impella 2.5 presented at the American College of Cardiology’s (ACC) 56th...